Sudden Sensorineural Hearing Loss Clinical Trial
Official title:
Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss is one of the most common emergencies in otorhinolaryngology, and its incidence is increasing year by year and tends to be younger. At present, the pathogenesis of sudden deafness is not clear and the individual treatment effects vary significantly. In order to break through this specific treatment bottleneck, this project pioneered the clinical application of the co-regulator nicotinamide adenine dinucleotide (NAD+) in the treatment of sudden deafness. Therefore, this project intends to use pure tone audiometry, speech audiometry, tinnitus disability scale THI, tinnitus subjective visual analog score method VAS, ear fullness subjective visual analog score method VAS for data analysis, and explore the safety of coenzyme I for injection on sudden deafness and efficacy assessment.
The recruited participants were patients with sudden hearing deafness, and the basic demographic data, including name, gender, age, medical history, etc., were collected. According to the inclusion and exclusion criteria, the patients were randomly divided into the experimental group and the control group. The experimental group was given conventional treatment + coenzyme I for injection, and the control group was given conventional treatment for 14 days. Baseline data were collected before treatment, and post-treatment data were collected on 3d, 7d, 14d，1m and 3m of treatment. Baseline data and post-treatment data included pure tone audiometry, speech audiometry, tinnitus THI scale, tinnitus VAS scale, tinnitus Stupid VAS scale. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04120116 -
FX-322 in Adults With Stable Sensorineural Hearing Loss
|
Phase 2 | |
| Recruiting |
NCT05403229 -
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
|
Phase 2 | |
| Not yet recruiting |
NCT05608161 -
Speech Perception Impairment Follow Complete Recovery of Sudden Sensorineural Hearing Loss
|
||
| Recruiting |
NCT04961099 -
Phase I Clinical Study of HY01 in Patients
|
Phase 1 | |
| Recruiting |
NCT06278129 -
Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease
|
||
| Recruiting |
NCT06249919 -
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04826237 -
Oral Statins and Protection From Hearing Loss
|
Phase 4 | |
| Not yet recruiting |
NCT04224909 -
Video HIT in Sudden Sensorineural Hearing Loss
|
||
| Not yet recruiting |
NCT06365775 -
Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss
|
||
| Not yet recruiting |
NCT06355102 -
The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics
|